BIOMAT Database Logo BIOMAT Database Logo

Strictosidine Synthase Triggered Enantioselective Synthesis of N-Substituted (S)-3,14,18,19-Tetrahydroangustines as Novel Topoisomerase I Inhibitors. 2017

Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
College of Pharmaceutical Sciences, Zhejiang University , Hangzhou 310058, China.

Monoterpenoid indole alkaloids (MIAs) comprise an important class of molecules for drug discovery, and they have variant carbon skeletons with prominent bioactivities. For instance, in spite of limitations to their use, camptothecins are the only clinically approved topoisomerase I (Top1) inhibitors. The enzyme strictosidine synthase, which is key for MIA biosynthesis, was applied to the enantioselective preparation of three N-substituted (S)-3,14,18,19-tetrahydroangustine (THA) derivatives. These non-camptothecin MIAs were shown to have moderate in vitro HepG2 cytotoxicity and Top1 inhibition activities. The (S)-configured MIAs had stronger cytotoxicity and Top1 inhibition than their chemically synthesized (R)-enantiomers, which aligned with the results of molecular dynamics simulations. A series of N-substituted (S)-THAs were then chemoenzymatically synthesized to investigate structure-activity relationships. The most active analogue observed was the N-(2-Cl benzoyl)-substituted derivative (7i). Insight into the binding mode of 7i and a Top1-DNA covalent complex was investigated by molecular dynamics simulations, which will facilitate future efforts to optimize the Top1 inhibitory activities of non-camptothecin MIAs.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D056945 Hep G2 Cells A human liver tumor cell line used to study a variety of liver-specific metabolic functions. Cell Line, Hep G2,Cell Line, Hepatoblastoma G2,Hep G2 Cell Line,HepG2 Cells,Hepatoblastoma G2 Cell Line,Cell, Hep G2,Cell, HepG2,Cells, Hep G2,Cells, HepG2,Hep G2 Cell,HepG2 Cell
D059004 Topoisomerase I Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE I. DNA Topoisomerase I Inhibitor,DNA Topoisomerase III Inhibitor,DNA Topoisomerase III Inhibitors,DNA Type 1 Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitors,Topoisomerase 1 Inhibitor,Topoisomerase 1 Inhibitors,Topoisomerase 3 Inhibitor,Topoisomerase 3 Inhibitors,Topoisomerase I Inhibitor,Topoisomerase III Inhibitor,Topoisomerase III Inhibitors,DNA Topoisomerase I Inhibitors,DNA Type 1 Topoisomerase Inhibitors,1 Inhibitor, Topoisomerase,3 Inhibitor, Topoisomerase,3 Inhibitors, Topoisomerase,I Inhibitor, Topoisomerase,III Inhibitor, Topoisomerase,III Inhibitors, Topoisomerase,Inhibitor, Topoisomerase 1,Inhibitor, Topoisomerase 3,Inhibitor, Topoisomerase I,Inhibitor, Topoisomerase III,Inhibitors, Topoisomerase 1,Inhibitors, Topoisomerase 3,Inhibitors, Topoisomerase I,Inhibitors, Topoisomerase III
D019759 Carbon-Nitrogen Lyases Enzymes that catalyze the cleavage of a carbon-nitrogen bond by means other than hydrolysis or oxidation. Subclasses are the AMMONIA-LYASES, the AMIDINE-LYASES, the amine-lyases, and other carbon-nitrogen lyases. EC 4.3. Carbon Nitrogen Lyases,Lyases, Carbon-Nitrogen

Related Publications

Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Synthesis and kinetic evaluation of S- and N-substituted cysteinylglycines as inhibitors of glyoxalase I.
January 1977, Journal of medicinal chemistry,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.
August 2008, Journal of medicinal chemistry,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Synthesis of aryl-substituted naphthalenoids as potent topoisomerase inhibitors.
January 2014, Medicinal chemistry (Shariqah (United Arab Emirates)),
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
January 2012, Bioorganic & medicinal chemistry letters,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Synthesis of novel benzoxanthone analogues as non-Camptothecin topoisomerase I inhibitors.
June 2012, Journal of enzyme inhibition and medicinal chemistry,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors.
March 2011, Bioorganic & medicinal chemistry,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors.
August 2015, European journal of medicinal chemistry,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors.
February 2016, Bioorganic & medicinal chemistry letters,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
Novel camptothecin derivatives as topoisomerase I inhibitors.
May 2009, Expert opinion on therapeutic patents,
Yunrui Cai, and Huajian Zhu, and Zaccary Alperstein, and Wenjun Yu, and Artem Cherkasov, and Hongbin Zou
3-Arylisoquinolines as novel topoisomerase I inhibitors.
January 2011, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!